Sino Biopharmaceutical (SMZ1) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SMZ1 Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Sino

Biopharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SMZ1 Stock 12 Month Forecast

Average Price Target

€1.12

▲(31.64% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is €1.12 with a high forecast of €1.35 and a low forecast of €1.02. The average price target represents a 31.64% change from the last price of €0.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.3513059865,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.118915785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.015631251,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.02</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Dec<br/>2024","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.951,0.9817927681923077,1.0125855363846152,1.043378304576923,1.0741710727692306,1.1049638409615383,1.135756609153846,1.1665493773461537,1.1973421455384614,1.228134913730769,1.2589276819230768,1.2897204501153845,1.3205132183076922,{"y":1.3513059865,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.951,0.9639165988461538,0.9768331976923077,0.9897497965384615,1.0026663953846153,1.0155829942307693,1.028499593076923,1.0414161919230769,1.0543327907692308,1.0672493896153845,1.0801659884615384,1.0930825873076924,1.105999186153846,{"y":1.118915785,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.951,0.9559716346923076,0.9609432693846154,0.965914904076923,0.9708865387692308,0.9758581734615385,0.9808298081538461,0.9858014428461539,0.9907730775384616,0.9957447122307692,1.0007163469230769,1.0056879816153848,1.0106596163076924,{"y":1.015631251,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.344,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.344,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.344,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.344,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.315,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.416,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.403,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.384,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.448,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.473,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.554,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.799,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.951,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€1.35

Average Price Target€1.12

Lowest Price Target€1.02

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anita Wei

UBS

€1.35

Buy

58.46%

Upside

Reiterated

09/29/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from UBS

Tony Ren

Macquarie

€0.77→€1.08

Buy

27.29%

Upside

Reiterated

09/08/25

Sino Biopharmaceutical (SBMFF) Gets a Buy from Macquarie

Jialin Zhang

Nomura

€0.85→€1.01

Buy

19.11%

Upside

Reiterated

08/19/25

Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)

John Yung

Citi

€0.97→€1.19

Buy

40.28%

Upside

Reiterated

08/19/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from Citi

Jill Wu

CMB International Securities

€1.04

Buy

22.09%

Upside

Initiated

08/01/25

Sino Biopharmaceutical: Innovation-Driven Growth and Strong Financials Justify Buy Rating

Michael Luo CFA

CLSA

€0.77→€1.02

Buy

19.50%

Upside

Reiterated

07/21/25

CLSA Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)

Ziyi Chen

Goldman Sachs

€0.43→€0.68

Buy

-19.60%

Downside

Reiterated

07/09/25

Goldman Sachs Remains a Buy on Sino Biopharmaceutical (SBMFF)

Linda Shu

HSBC

€0.42→€0.56

Buy

-33.76%

Downside

Reiterated

06/04/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from HSBC

Rebecca Liang

Bernstein

€0.33

Hold

-61.03%

Downside

Reiterated

03/20/25

Bernstein Sticks to Their Hold Rating for Sino Biopharmaceutical (SBMFF)

Chris Lui

Jefferies

€0.77→€0.55

Buy

-35.06%

Downside

Reiterated

10/25/24

Sino Biopharmaceutical (SBMFF) Receives a Buy from Jefferies

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anita Wei

UBS

€1.35

Buy

58.46%

Upside

Reiterated

09/29/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from UBS

Tony Ren

Macquarie

€0.77→€1.08

Buy

27.29%

Upside

Reiterated

09/08/25

Sino Biopharmaceutical (SBMFF) Gets a Buy from Macquarie

Jialin Zhang

Nomura

€0.85→€1.01

Buy

19.11%

Upside

Reiterated

08/19/25

Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)

John Yung

Citi

€0.97→€1.19

Buy

40.28%

Upside

Reiterated

08/19/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from Citi

Jill Wu

CMB International Securities

€1.04

Buy

22.09%

Upside

Initiated

08/01/25

Sino Biopharmaceutical: Innovation-Driven Growth and Strong Financials Justify Buy Rating

Michael Luo CFA

CLSA

€0.77→€1.02

Buy

19.50%

Upside

Reiterated

07/21/25

CLSA Reaffirms Their Buy Rating on Sino Biopharmaceutical (SBMFF)

Ziyi Chen

Goldman Sachs

€0.43→€0.68

Buy

-19.60%

Downside

Reiterated

07/09/25

Goldman Sachs Remains a Buy on Sino Biopharmaceutical (SBMFF)

Linda Shu

HSBC

€0.42→€0.56

Buy

-33.76%

Downside

Reiterated

06/04/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from HSBC

Rebecca Liang

Bernstein

€0.33

Hold

-61.03%

Downside

Reiterated

03/20/25

Bernstein Sticks to Their Hold Rating for Sino Biopharmaceutical (SBMFF)

Chris Lui

Jefferies

€0.77→€0.55

Buy

-35.06%

Downside

Reiterated

10/25/24

Sino Biopharmaceutical (SBMFF) Receives a Buy from Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sino Biopharmaceutical

1 Month

xxx

Success Rate

3/3 ratings generated profit

Average Return

+10.20%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +10.20% per trade.

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+51.67%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +51.67% per trade.

1 Year

Michael Luo CFACLSA

Success Rate

3/3 ratings generated profit

Average Return

+73.67%

reiterated a buy rating 3 months ago

Copying Michael Luo CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +73.67% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+73.67%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +73.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMZ1 Analyst Recommendation Trends

Rating

Apr 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SMZ1 has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. SMZ1 average Analyst price target in the past 3 months is 1.12.

Each month's total comprises the sum of three months' worth of ratings.

SMZ1 Financial Forecast

SMZ1 Earnings Forecast

Next quarter’s earnings estimate for SMZ1 is €0.01 with a range of €0.01 to €0.01. The previous quarter’s EPS was €0.02. SMZ1 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SMZ1 has Outperformed its overall industry.

SMZ1 Sales Forecast

Next quarter’s sales forecast for SMZ1 is €1.93B with a range of €1.93B to €1.93B. The previous quarter’s sales results were €2.07B. SMZ1 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SMZ1 has Preformed in-line its overall industry.

SMZ1 Stock Forecast FAQ

What is DE:SMZ1’s average 12-month price target, according to analysts?

Based on analyst ratings, Sino Biopharmaceutical’s 12-month average price target is 1.12.

What is DE:SMZ1’s upside potential, based on the analysts’ average price target?

Sino Biopharmaceutical has 31.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sino Biopharmaceutical a Buy, Sell or Hold?

Sino Biopharmaceutical has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sino Biopharmaceutical’s share price target?

The average share price target for Sino Biopharmaceutical is 1.12. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1.35 ,and the lowest forecast is €1.02. The average share price target represents 31.64% Increase from the current price of €0.85.

What do analysts say about Sino Biopharmaceutical?

Sino Biopharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Sino Biopharmaceutical?

To buy shares of DE:SMZ1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sino Biopharmaceutical (SMZ1) Stock Forecast & Price Target

SMZ1 Analyst Ratings

SMZ1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sino Biopharmaceutical

SMZ1 Analyst Recommendation Trends

SMZ1 Financial Forecast

SMZ1 Earnings Forecast

SMZ1 Sales Forecast

SMZ1 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts